Advertisement

U.S. Markets closed

S&P Futures
3,828.25
+2.75(+0.07%)
Dow Futures
30,958.00
+25.00(+0.08%)
Nasdaq Futures
11,684.50
+10.25(+0.09%)
Russell 2000 Futures
1,739.60
+1.30(+0.07%)
Crude Oil
111.32
-0.44(-0.39%)
Gold
1,823.10
+1.90(+0.10%)

Advertisement

Blueprint Medicines Corporation (BPMC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

53.46

-3.92

(-6.83%)

At close: 04:00PM EDT

53.00

-0.46

(-0.86%)

After hours:

04:42PM EDT

Advertisement

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Neutralpattern detected

All

PR Newswire
Blueprint Medicines Appoints Habib Dable to its Board of Directors
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of Acceleron Pharma from 2016 to 2021, brings nearly 30 years of experience in strategic leadership, commercial growth and organizational scale across global pharmaceutical and emerging biotechnology companies.
- PortsToronto Announces New President & Chief Executive Officer
  CNW Group
- Limbach Holdings Inc. Expands Technology Focus and Appoints Christos Ruci to Chief Information Officer
  Business Wire
Zacks
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.
Investor's Business Daily
Blueprint Stock Dives On The FDA's Tricky New Requirement For Its Leading Drug
The FDA recommended Blueprint Medicines change the ultimate goal of a midstage study, leading BPMC stock to crumble Thursday.